Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer

NCT00436566 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT00436566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00436566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Plus Trastuzumab With Lapatinib in Patients With Resected HER2 + Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2007
Completion date
July 22, 2019
Enrollment
122 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiac toxicity